T. Graves

发表

Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast?

Yihong Wang, Shaolei Lu, E. Yakirevich, 2017, Clinical breast cancer.

Carcinoma In Situ of the Breast: Ductal and Lobular Origin

K. Bland, T. Graves, 2009 .

Bisphosphonate use in metastatic breast cancer

T. Graves, 1999 .

Three-Dimensional Bioabsorbable Tissue Marker Placement is Associated with Decreased Tumor Bed Volume Among Patients Receiving Radiation Therapy for Breast Cancer.

D. Wazer, J. Hepel, K. Sindhu, 2019, Practical radiation oncology.

The rationale, technique, and feasibility of partial breast irradiation using noninvasive image-guided breast brachytherapy.

D. Wazer, J. Hepel, J. Hiatt, 2014, Brachytherapy.

Surgery for early and minimally invasive breast cancer.

K. Bland, T. Graves, 1996, Current opinion in oncology.

Phase II Trial of Accelerated Partial Breast Irradiation (APBI) using Non-Invasive Image-Guided Breast Brachytherapy (NIBB).

D. Wazer, J. Hepel, K. Leonard, 2020, International journal of radiation oncology, biology, physics.

Five fraction accelerated partial breast irradiation using noninvasive image-guided breast brachytherapy: Feasibility and acute toxicity.

D. Wazer, T. Dipetrillo, C. Yashar, 2017, Brachytherapy.

Microinvasive breast cancer and the role of sentinel lymph node biopsy

Yihong Wang, Sean M. Hacking, Lijuan Wang, 2021, Scientific Reports.

A Phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer

B. Cady, D. Lowther, D. Wazer, 2001 .

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

Yihong Wang, A. Brodsky, Jinjun Xiong, 2016, BMC Cancer.

Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer

Yihong Wang, A. Brodsky, Shaolei Lu, 2019, BMC Cancer.

Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

D. Dizon, W. Sikov, R. Legare, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study

David A. Edmondson, A. Stuckey, M. Lopresti, 2021, Breast Cancer Research and Treatment.

Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer.

Kenneth Ulin, B. Cady, K. Ulin, 2002, International journal of radiation oncology, biology, physics.

Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer

Yihong Wang, A. Amin, D. Dizon, 2021, Breast Cancer Research and Treatment.

Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.

M. Mainiero, S. Koelliker, M. Chung, 2010, AJR. American journal of roentgenology.

A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes.

K. Bland, D. Winchester, D. Winchester, 1998, Journal of the American College of Surgeons.

Distress: Characterizing What Causes the Thermometer to Shift in Patients with Newly Diagnosed Breast Cancer Attending a Multidisciplinary Clinic

M. Lopresti, D. Dizon, K. Leonard, 2019, Annals of Surgical Oncology.

Neoadjuvant q4week carboplatin and weekly paclitaxel {+/-} trastuzumab in resectable and locally advanced breast cancer: A Brown University Oncology Group (BrUOG) study

D. Dizon, W. Sikov, J. Gass, 2005 .